FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997806446> ?p ?o ?g. }

• W2997806446 endingPage "e246" @default.
• W2997806446 startingPage "e238" @default.
• W2997806446 abstract "Background Data to inform surveillance and treatment for leukaemia predisposition syndromes are scarce and recommendations are largely based on expert opinion. This study aimed to investigate the clinical features and outcomes of patients with myelodysplastic syndrome or acute myeloid leukaemia and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developing myeloid malignancies. Methods We did a multicentre, retrospective, cohort study in collaboration with the North American Shwachman-Diamond Syndrome Registry. We reviewed patient medical records from 17 centres in the USA and Canada. Patients with a genetic (biallelic mutations in the SBDS gene) or clinical diagnosis (cytopenias and pancreatic dysfunction) of Shwachman-Diamond syndrome who developed myelodysplastic syndrome or acute myeloid leukaemia were eligible without additional restriction. Medical records were reviewed between March 1, 2001, and Oct 5, 2017. Masked central review of bone marrow pathology was done if available to confirm leukaemia or myelodysplastic syndrome diagnosis. We describe the clinical features and overall survival of these patients. Findings We initially identified 37 patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia. 27 patients had samples available for central pathology review and were reclassified accordingly (central diagnosis concurred with local in 15 [56%] cases), 10 had no samples available and were classified based on the local review data, and 1 patient was excluded at this stage as not eligible. 36 patients were included in the analysis, of whom 10 (28%) initially presented with acute myeloid leukaemia and 26 (72%) initially presented with myelodysplastic syndrome. With a median follow-up of 4·9 years (IQR 3·9–8·4), median overall survival for patients with myelodysplastic syndrome was 7·7 years (95% CI 0·8–not reached) and 0·99 years (95% CI 0·2–2·4) for patients with acute myeloid leukaemia. Overall survival at 3 years was 11% (95% CI 1–39) for patients with leukaemia and 51% (29–68) for patients with myelodysplastic syndrome. Management and surveillance were variable. 18 (69%) of 26 patients with myelodysplastic syndrome received upfront therapy (14 haematopoietic stem cell transplantation and 4 chemotherapy), 4 (15%) patients received no treatment, 2 (8%) had unavailable data, and 2 (8%) progressed to acute myeloid leukaemia before receiving treatment. 12 patients received treatment for acute myeloid leukaemia—including the two patients initially diagnosed with myelodysplastic who progressed— two (16%) received HSCT as initial therapy and ten (83%) received chemotherapy with intent to proceed with HSCT. 33 (92%) of 36 patients (eight of ten with leukaemia and 25 of 26 with myelodysplastic syndrome) were known to have Shwachman-Diamond syndrome before development of a myeloid malignancy and could have been monitored with bone marrow surveillance. Bone marrow surveillance before myeloid malignancy diagnosis was done in three (33%) of nine patients with leukaemia for whom surveillance status was confirmed and 11 (46%) of 24 patients with myelodysplastic syndrome. Patients monitored had a 3-year overall survival of 62% (95% CI 32–82; n=14) compared with 28% (95% CI 10–50; n=19; p=0·13) without surveillance. Six (40%) of 15 patients with available longitudinal data developed myelodysplastic syndrome in the setting of stable blood counts. Interpretation Our results suggest that prognosis is poor for patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia owing to both therapy-resistant disease and treatment-related toxicities. Improved surveillance algorithms and risk stratification tools, studies of clonal evolution, and prospective trials are needed to inform effective prevention and treatment strategies for leukaemia predisposition in patients with Shwachman-Diamond syndrome. Funding National Institute of Health. Data to inform surveillance and treatment for leukaemia predisposition syndromes are scarce and recommendations are largely based on expert opinion. This study aimed to investigate the clinical features and outcomes of patients with myelodysplastic syndrome or acute myeloid leukaemia and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developing myeloid malignancies. We did a multicentre, retrospective, cohort study in collaboration with the North American Shwachman-Diamond Syndrome Registry. We reviewed patient medical records from 17 centres in the USA and Canada. Patients with a genetic (biallelic mutations in the SBDS gene) or clinical diagnosis (cytopenias and pancreatic dysfunction) of Shwachman-Diamond syndrome who developed myelodysplastic syndrome or acute myeloid leukaemia were eligible without additional restriction. Medical records were reviewed between March 1, 2001, and Oct 5, 2017. Masked central review of bone marrow pathology was done if available to confirm leukaemia or myelodysplastic syndrome diagnosis. We describe the clinical features and overall survival of these patients. We initially identified 37 patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia. 27 patients had samples available for central pathology review and were reclassified accordingly (central diagnosis concurred with local in 15 [56%] cases), 10 had no samples available and were classified based on the local review data, and 1 patient was excluded at this stage as not eligible. 36 patients were included in the analysis, of whom 10 (28%) initially presented with acute myeloid leukaemia and 26 (72%) initially presented with myelodysplastic syndrome. With a median follow-up of 4·9 years (IQR 3·9–8·4), median overall survival for patients with myelodysplastic syndrome was 7·7 years (95% CI 0·8–not reached) and 0·99 years (95% CI 0·2–2·4) for patients with acute myeloid leukaemia. Overall survival at 3 years was 11% (95% CI 1–39) for patients with leukaemia and 51% (29–68) for patients with myelodysplastic syndrome. Management and surveillance were variable. 18 (69%) of 26 patients with myelodysplastic syndrome received upfront therapy (14 haematopoietic stem cell transplantation and 4 chemotherapy), 4 (15%) patients received no treatment, 2 (8%) had unavailable data, and 2 (8%) progressed to acute myeloid leukaemia before receiving treatment. 12 patients received treatment for acute myeloid leukaemia—including the two patients initially diagnosed with myelodysplastic who progressed— two (16%) received HSCT as initial therapy and ten (83%) received chemotherapy with intent to proceed with HSCT. 33 (92%) of 36 patients (eight of ten with leukaemia and 25 of 26 with myelodysplastic syndrome) were known to have Shwachman-Diamond syndrome before development of a myeloid malignancy and could have been monitored with bone marrow surveillance. Bone marrow surveillance before myeloid malignancy diagnosis was done in three (33%) of nine patients with leukaemia for whom surveillance status was confirmed and 11 (46%) of 24 patients with myelodysplastic syndrome. Patients monitored had a 3-year overall survival of 62% (95% CI 32–82; n=14) compared with 28% (95% CI 10–50; n=19; p=0·13) without surveillance. Six (40%) of 15 patients with available longitudinal data developed myelodysplastic syndrome in the setting of stable blood counts. Our results suggest that prognosis is poor for patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia owing to both therapy-resistant disease and treatment-related toxicities. Improved surveillance algorithms and risk stratification tools, studies of clonal evolution, and prospective trials are needed to inform effective prevention and treatment strategies for leukaemia predisposition in patients with Shwachman-Diamond syndrome." @default.
• W2997806446 created "2020-01-10" @default.
• W2997806446 creator A5000386786 @default.
• W2997806446 creator A5000527476 @default.
• W2997806446 creator A5006230191 @default.
• W2997806446 creator A5008503600 @default.
• W2997806446 creator A5008762363 @default.
• W2997806446 creator A5009626650 @default.
• W2997806446 creator A5009781691 @default.
• W2997806446 creator A5010786159 @default.
• W2997806446 creator A5014618567 @default.
• W2997806446 creator A5027649336 @default.
• W2997806446 creator A5028145044 @default.
• W2997806446 creator A5029542794 @default.
• W2997806446 creator A5031092064 @default.
• W2997806446 creator A5037881595 @default.
• W2997806446 creator A5043703349 @default.
• W2997806446 creator A5045246519 @default.
• W2997806446 creator A5045753320 @default.
• W2997806446 creator A5046074908 @default.
• W2997806446 creator A5046777498 @default.
• W2997806446 creator A5051427859 @default.
• W2997806446 creator A5053216827 @default.
• W2997806446 creator A5054223683 @default.
• W2997806446 creator A5065735225 @default.
• W2997806446 creator A5067712388 @default.
• W2997806446 creator A5068594394 @default.
• W2997806446 creator A5071412954 @default.
• W2997806446 creator A5071532151 @default.
• W2997806446 creator A5082415828 @default.
• W2997806446 creator A5084293954 @default.
• W2997806446 creator A5084420698 @default.
• W2997806446 creator A5085802114 @default.
• W2997806446 creator A5087115676 @default.
• W2997806446 date "2020-03-01" @default.
• W2997806446 modified "2023-10-10" @default.
• W2997806446 title "Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study" @default.
• W2997806446 cites W1969881384 @default.
• W2997806446 cites W1992989994 @default.
• W2997806446 cites W2018283514 @default.
• W2997806446 cites W2024058673 @default.
• W2997806446 cites W2047366930 @default.
• W2997806446 cites W2053749374 @default.
• W2997806446 cites W2060941753 @default.
• W2997806446 cites W2064224156 @default.
• W2997806446 cites W2065300348 @default.
• W2997806446 cites W2074423820 @default.
• W2997806446 cites W2080104001 @default.
• W2997806446 cites W2084697300 @default.
• W2997806446 cites W2093274439 @default.
• W2997806446 cites W2095174883 @default.
• W2997806446 cites W2115504023 @default.
• W2997806446 cites W2119607268 @default.
• W2997806446 cites W2126366711 @default.
• W2997806446 cites W2133832867 @default.
• W2997806446 cites W2339658711 @default.
• W2997806446 cites W2460137265 @default.
• W2997806446 cites W2539046372 @default.
• W2997806446 cites W2549790759 @default.
• W2997806446 cites W2587066646 @default.
• W2997806446 cites W2589090458 @default.
• W2997806446 cites W2753494561 @default.
• W2997806446 cites W2766437865 @default.
• W2997806446 cites W2805881413 @default.
• W2997806446 cites W2816020997 @default.
• W2997806446 cites W2891905200 @default.
• W2997806446 cites W2898284215 @default.
• W2997806446 doi "https://doi.org/10.1016/s2352-3026(19)30206-6" @default.
• W2997806446 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7984274" @default.
• W2997806446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31879230" @default.
• W2997806446 hasPublicationYear "2020" @default.
• W2997806446 type Work @default.
• W2997806446 sameAs 2997806446 @default.
• W2997806446 citedByCount "58" @default.
• W2997806446 countsByYear W29978064462020 @default.
• W2997806446 countsByYear W29978064462021 @default.
• W2997806446 countsByYear W29978064462022 @default.
• W2997806446 countsByYear W29978064462023 @default.
• W2997806446 crossrefType "journal-article" @default.
• W2997806446 hasAuthorship W2997806446A5000386786 @default.
• W2997806446 hasAuthorship W2997806446A5000527476 @default.
• W2997806446 hasAuthorship W2997806446A5006230191 @default.
• W2997806446 hasAuthorship W2997806446A5008503600 @default.
• W2997806446 hasAuthorship W2997806446A5008762363 @default.
• W2997806446 hasAuthorship W2997806446A5009626650 @default.
• W2997806446 hasAuthorship W2997806446A5009781691 @default.
• W2997806446 hasAuthorship W2997806446A5010786159 @default.
• W2997806446 hasAuthorship W2997806446A5014618567 @default.
• W2997806446 hasAuthorship W2997806446A5027649336 @default.
• W2997806446 hasAuthorship W2997806446A5028145044 @default.
• W2997806446 hasAuthorship W2997806446A5029542794 @default.
• W2997806446 hasAuthorship W2997806446A5031092064 @default.
• W2997806446 hasAuthorship W2997806446A5037881595 @default.
• W2997806446 hasAuthorship W2997806446A5043703349 @default.
• W2997806446 hasAuthorship W2997806446A5045246519 @default.
• W2997806446 hasAuthorship W2997806446A5045753320 @default.
• W2997806446 hasAuthorship W2997806446A5046074908 @default.
• W2997806446 hasAuthorship W2997806446A5046777498 @default.

• next